众生药业：昂拉地韦片已获得国家药监局批准上市

Core Viewpoint - Zhongsheng Pharmaceutical has developed Anglavei tablets, the world's first RNA polymerase PB2 protein inhibitor for influenza, which has shown superior efficacy compared to existing antiviral drugs [1] Group 1: Product Information - Anglavei tablets have a clear mechanism of action and global intellectual property rights, specifically targeting adult patients with uncomplicated type A influenza [1] - In vitro virology studies indicate that Anglavei demonstrates significantly better inhibition of various type A influenza viruses compared to neuraminidase inhibitors like Oseltamivir and endonuclease inhibitors like Baloxavir [1] - Anglavei is effective against Oseltamivir-resistant strains, Baloxavir-resistant strains, and highly pathogenic avian influenza virus strains [1] Group 2: Clinical Trials and Approval - The Phase III clinical trial comparing Anglavei with Oseltamivir capsules and a placebo for adult type A influenza patients has yielded positive results, meeting the predefined primary efficacy endpoints with good safety [1] - Anglavei tablets have received approval from the National Medical Products Administration, and the company is actively advancing the commercialization of this product [1]